Exploring height outcomes with adjuvant aromatase inhibition in growth hormone-deficient male survivors of childhood cancer.

Netanya I Pollock Minkeun SongAlexander J WolfYimei Li Colin Patrick HawkesNiloofaralsadat MotamediMichelle R DenburgSogol Mostoufi-Moab

Published in: Pediatric blood & cancer (2024)

Adjuvant AI was not associated with increased FAH in male CCS compared with GH monotherapy. Future work is needed to determine the optimal adjunctive treatment to maximize FAH for this population.

Keyphrases

growth hormone
childhood cancer
young adults
early stage
combination therapy
body mass index
artificial intelligence
current status
open label
clinical trial
type diabetes
metabolic syndrome
adipose tissue
randomized controlled trial